Carprieve Tablets 50mg

Kraj: Wielka Brytania

Język: angielski

Źródło: VMD (Veterinary Medicines Directorate)

Składnik aktywny:

Carprofen

Dostępny od:

Norbrook Laboratories Limited

Kod ATC:

QM01AE91

INN (International Nazwa):

Carprofen

Forma farmaceutyczna:

Tablet

Typ recepty:

POM-V - Prescription Only Medicine – Veterinarian

Grupa terapeutyczna:

Dogs

Dziedzina terapeutyczna:

Anti Inflammatory NSAID

Status autoryzacji:

Authorized

Data autoryzacji:

2003-09-05

Charakterystyka produktu

Revised: 28
th
January 2009
AN: 02049/2008
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Carprieve Tablets 50mg
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE:
Each tablet contains:
Carprofen
50 mg
EXCIPIENTS:
For a full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Tablet
A white/off white circular tablet of diameter 8 mm, 50 embossed on one
side and a
single break line on the other side.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For analgesia and reduction of chronic inflammation, for example in
degenerative
joint disease, in dogs.
Carprieve Tablets can also be used in the management of post-operative
pain.
4.3
CONTRAINDICATIONS
The use of Carprieve Tablets is contraindicated in the cat, and the
inadvertent
administration of oral carprofen tablets may induce life-threatening
conditions in this
species.
Do not exceed the stated dose.
Do not administer NSAIDs concurrently or within 24 hours of each
other. Some
NSAIDs may be highly bound to plasma proteins and compete with other
highly
bound drugs, which can lead to toxic effects.
Do not use in dogs suffering from cardiac, hepatic or renal disease,
where there is a
possibility of gastrointestinal ulceration or bleeding, or where there
is evidence of a
blood dyscrasia or hypersensitivity to the product.
Revised: 28
th
January 2009
AN: 02049/2008
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Use in dogs less than 6 weeks of age, or in aged animals, may involve
additional risk.
If such use cannot be avoided, such dogs may require a reduced dosage
and careful
clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there
is a potential
risk of increased renal toxicity.
NSAIDs
can
cause
inhibition
of
phagocytosis
and
hence
in
the
treatment
of
inflammatory conditions associated with bacterial infection,
appropriate concurrent
antimicrobial therapy should be instigated.
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR